10 Best Indian Stocks for Next 10 Years

6) Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Number of Hedge Fund Holders: 16

Dr. Reddy’s Laboratories Limited (NYSE:RDY) operates as an integrated pharmaceutical company worldwide.

Wall Street remains optimistic about Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s long-term growth trajectory as it invested $620 million in its wholly-owned subsidiary, DRL SA, Switzerland. This investment is for the acquisition of Nicotinell and related brands. This move, which is a related party transaction that has been done at arm’s length, focuses on bolstering its pharmaceutical portfolio and strengthening its market position.

Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s competitive advantage revolves around brand intangibles in select emerging markets. Its strategic partnerships, together with a diverse product pipeline, should continue to aid its revenue growth in the upcoming quarters. Dr. Reddy’s Laboratories Limited (NYSE:RDY) believes that a strong pipeline of complex products and biosimilars should continue to drive earnings growth for the foreseeable future.

The company continues to focus on the branded generics market in India, and experts believe that this market is expected to grow. Dr. Reddy’s Laboratories Limited (NYSE:RDY) focuses on innovation and patent-protected offerings.  It is emphasizing on true innovation and launching patent-protected products. Wall Street experts opine that the leading pharmaceutical giant has positioned itself for continued growth, with a strong focus on partnerships, product pipeline diversification, and market expansion.

Analysts at Barclays upped their price target on the shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) from $81.00 to $87.00, giving an “Overweight” rating on 30^th July. As per Insider Monkey’s Q2 2024 data, 16 hedge funds were long Dr. Reddy’s Laboratories Limited (NYSE:RDY).